PHASQ — PhaseBio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$3.73m
- $10.83m
PhaseBio Pharmaceuticals Inc expected to post a loss of 66 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Biogen, FTC Solar, Palo Alto Networks
PhaseBio rises on positive data from blood clotting drug trial
U.S. RESEARCH ROUNDUP- Beyond Meat, Kennametal, McDonald's
Brief: Phasebio Pharmaceuticals Reports Fourth Quarter And Full-Year 2021 Financial Results And Provides Recent Business Highlights
Brief: Phasebio Pharmaceuticals Announces Bentracimab Manufacturing Update
Brief: PhaseBio Pharmaceuticals To Participate In Cowen 42nd Annual Health Care Conference
Brief: PhaseBio Announces Bentracimab Phase 2B Trial Data Accepted For Late Breaking Clinical Research Presentation
Brief: Phasebio Pharmaceuticals Inc Voluntarily Ending Its Phase 2B Trial Of Pemziviptadil (Pb1046) In PAH Due To Covid-19 Impacts On Manufacturing
Brief: Phasebio Announces Publication Of Interim Results From Pivotal Reverse-It Phase 3 Trial Of Bentracimab In NEJM Evidence
Brief: Phasebio Names Jonathan Birchall As Chief Commercial Officer
Brief: PhaseBio Announces Interim Results from Pivotal REVERSE-IT Phase 3 Trial of Bentracimab
PhaseBio Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Phasebio Reports Third-Quarter 2021 Financial Results And Recent Business Highlights
Brief: PhaseBio Announces Topline Results From Phase 2b Trial For Bentracimab
U.S. RESEARCH ROUNDUP- Boeing, Monster Beverage, Workday
PhaseBio Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: PhaseBio Reports Q2 Loss Per Share Of $0.60
PhaseBio Pharmaceuticals Inc expected to post a loss of 46 cents a share - Earnings Preview